Evaluation of the Effect of Ixekizumab on the Pharmacokinetics of Cytochrome P450 Substrates in Patients With Moderate-to-Severe Plaque Psoriasis

Trial Profile

Evaluation of the Effect of Ixekizumab on the Pharmacokinetics of Cytochrome P450 Substrates in Patients With Moderate-to-Severe Plaque Psoriasis

Active, no longer recruiting
Phase of Trial: Phase I

Latest Information Update: 18 Aug 2017

At a glance

  • Drugs Caffeine (Primary) ; Dextromethorphan (Primary) ; Ixekizumab (Primary) ; Midazolam (Primary) ; Omeprazole (Primary) ; Vitamin K (Primary) ; Warfarin (Primary)
  • Indications Plaque psoriasis
  • Focus Pharmacokinetics
  • Sponsors Eli Lilly
  • Most Recent Events

    • 04 Aug 2017 Status changed from recruiting to active, no longer recruiting.
    • 23 Dec 2016 Status changed from not yet recruiting to recruiting.
    • 19 Dec 2016 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top